Vabysmo Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Vabysmo Indications
Indications
Vabysmo Dosage and Administration
Adult
See full labeling. Give by intravitreal inj. nAMD: 6mg (0.05mL) once every 4 weeks (approx. every 28 ± 7 days, monthly) for the 1st 4 doses, followed by optical coherence tomography and visual acuity evaluations 8 and 12 weeks later to determine whether to give a 6mg (0.05mL) dose on one of the following 3 regimens: (1) Weeks 28 and 44; (2) Weeks 24, 36 and 48; or (3) Weeks 20, 28, 36 and 44. DME (Regimen 1): 6mg (0.05mL) once every 4 weeks for at least 4 doses, then may be adjusted by up to 4 week interval increments or reductions of up to 8 week interval increments based on CST and visual acuity evaluations; or (Regimen 2): 6mg (0.05mL) once every 4 weeks for the 1st 6 doses, followed by 6mg (0.05mL) every 8 weeks.
Children
Vabysmo Contraindications
Contraindications
Vabysmo Boxed Warnings
Not Applicable
Vabysmo Warnings/Precautions
Warnings/Precautions
Vabysmo Pharmacokinetics
Elimination
Vabysmo Interactions
Not Applicable
Vabysmo Adverse Reactions
Adverse Reactions
Vabysmo Clinical Trials
See Literature
Vabysmo Note
Not Applicable
Vabysmo Patient Counseling
See Literature